Brokerages Set Omnicell, Inc. (NASDAQ:OMCL) Target Price at $43.00

Omnicell, Inc. (NASDAQ:OMCL) has been assigned an average recommendation of “Hold” from the seven ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $43.00.

Several equities research analysts have weighed in on the company. Weiss Ratings restated a “sell (d+)” rating on shares of Omnicell in a research note on Wednesday, October 8th. Benchmark upped their price objective on Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 9th.

Omnicell Trading Up 1.0%

OMCL opened at $46.25 on Friday. The company has a quick ratio of 1.21, a current ratio of 1.44 and a debt-to-equity ratio of 0.14. Omnicell has a twelve month low of $22.66 and a twelve month high of $47.69. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of 107.56, a P/E/G ratio of 5.01 and a beta of 0.83. The company has a 50-day simple moving average of $35.92 and a 200 day simple moving average of $32.38.

Institutional Investors Weigh In On Omnicell

Several hedge funds have recently modified their holdings of OMCL. WINTON GROUP Ltd bought a new position in Omnicell during the 2nd quarter worth $2,692,000. State of Alaska Department of Revenue raised its position in shares of Omnicell by 8.7% during the second quarter. State of Alaska Department of Revenue now owns 27,906 shares of the company’s stock worth $819,000 after acquiring an additional 2,242 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Omnicell by 1.3% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock worth $41,854,000 after acquiring an additional 17,680 shares during the last quarter. Intech Investment Management LLC lifted its stake in shares of Omnicell by 75.6% in the first quarter. Intech Investment Management LLC now owns 230,171 shares of the company’s stock worth $8,047,000 after acquiring an additional 99,104 shares during the period. Finally, Advantage Alpha Capital Partners LP bought a new stake in Omnicell in the second quarter valued at approximately $2,476,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.